Answers are grounded in this paper and cite their sources.
RIB combined with ET demonstrated improved progression-free survival (PFS) and overall survival (OS) in pts with HR+, HER2− MBC in pivotal MONALEESA (ML) trials. RW studies complement phase III trial data in a broader population. Herein, we report final analysis results from REACH AUT study.
No takes yet. Share an insight, caveat, or question.
Singer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: